The US Peptide Therapeutics Market has been projected at $52.6 billion in 2025 by Holt Law's market report, reflecting the combined scope of GLP-1 and non-GLP-1 peptide pipeline commercialisation pressure
Adherence is generally affected by a combination of capability (strength, dexterity, cognitive powers), opportunity (complexity, cost, availability) and motivation (intrinsic drivers, rewards, general mood).11 Based on this, it is possible to calculate relative differences in likely adherence with a quantitative analysis of typical disease impact, patient demographics, drug effects and device operating principles.12 By systematically analysing a drug delivery solution, it is possible to identify opportunities for improvement and determine the cost-benefit of investing in a wide range of design features
We typically recommend stopping these medications at least 2 months before attempting conception
Research suggests that GLP-1 medications may reduce this harmful fat depot as part of overall weight loss, though the mechanisms remain incompletely understood
Clinical study FY25_FL54, Data on file
